AT-rich interactive domain-containing protein 1A is a protein that in humans is encoded by the ARID1A gene. [5][6][7] ARID1A is a member of the SWI/SNF family, whose members have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes.

2024年12月24日 · ARID1A (AT-Rich Interaction Domain 1A) is a Protein Coding gene. Diseases associated with ARID1A include Coffin-Siris Syndrome 2 and Coffin-Siris Syndrome 1. Among its related pathways are Gene expression (Transcription) and MITF-M-dependent gene expression.

arid1a 是swi/snf这个 染色质重塑 复合物的一个亚基，在癌症中经常发生突变。其同源arid1b的缺失会导致arid1a突变的合成致死。但是这两个同源物之间的功能关系还没有被很好的解释。

A growing body of evidence shows that ARID1A, as a tumor suppressor gene, affects the occurrence and development of cancers. ARID1A plays an important role in cell cycle, DNA replication, DNA repair and transcriptional regulation, which might contribute to tumor formation, proliferation and migration.

最近，科学家们注意到，肿瘤中一个名为 ARID1A 的基因发生突变的患者更有可能对免疫检查点阻断疗法产生积极反应，其中这种免疫疗法的作用原理是让称为 T 细胞的抗癌免疫细胞处于“开启”状态，否则它们就会处于“关闭”状态。 由于这种ARID1A基因突变存在于许多癌症中，包括 子宫内膜癌 、 卵巢癌 、 结肠癌 、 胃癌 、 肝癌 和 胰腺癌，因此在一项新的研究中，来自索尔克研究所的研究人员想知道这种突变会如何影响治疗的敏感性，以及临床医生如何利用这些信息为每位患 …

2024年5月15日 · ARID1A loss in tumor cells triggers anti-tumor immunity via R-loop-derived cytosolic DNA and activation of the STING-type I interferon pathway, defining a molecular mechanism underlying ARID1A mutant anti-tumor immunity and immunotherapy response observed clinically.

ARID1A is a SWI/SNF subunit gene whose protein product binds DNA. ARID1A gene alterations result in loss of function. It is the most commonly mutated member of the SWI/SNF complex, being aberrant in ∼6% of cancers overall, including ovarian clear cell cancers (∼45% of patients) and uterine endometrioid cancers (∼37%).

2019年1月22日 · SWI/SNF是重要的染色质重塑复合物，ARID1A是 SWI/SNF的核心亚基，其在癌细胞中具有较高的突变率，是一种肿瘤抑制因子[1]。 本文对ARID1A在多种癌症中的作用机制进行了综述。 1 ARID1A的基本特征. 1.1 SWI/SNF染色质重塑复合物 在DNA复制、重组、修复及转录等过程中，染色质的包装及相应DNA分子发生改变，称为染色质重塑。 ATP依赖染色质重塑复合物和组蛋白共价修饰复合物一起参与染色质重塑，共同调控染色质的结构及基因表达[2]。 ATP …

2023年5月29日 · ARID1A和表皮生长因子受体 （EGFR）共突变导致EGFR酪氨酸激酶抑制剂（EGFR-TKI）疗效降低，免疫检查点抑制剂（ICI）临床获益增加。 ARID1A基因突变在细胞周期调控、代谢重编程和上皮-间充质转化中发挥作用。 本综述首次全面总结了ARID1A基因突变与肺癌的相关性，讨论了ARID1A作为新分子靶点的潜力。 肺癌发病率上升. 原发性肺癌的定义为起源于肺细胞的恶性肿瘤，大致分为两类，其中非小细胞肺癌（NSCLC）最常见，占所有诊断 …

2024年6月10日 · AT-rich interaction domain protein 1A (ARID1A), a SWI/SNF chromatin remodeling complex subunit, is frequently mutated across various cancer entities. Loss of ARID1A leads to DNA repair defects. Here, we show that ARID1A plays epigenetic roles to promote both DNA double-strand breaks (DSBs) repair pa …